Spotlight On... AstraZeneca moves quickly to shed another noncore drug in ProStrakan deal; India's Odisha state eyes drug manufacture parks; Chuikyo fee revisions in focus; and more...

U.K. multinational AstraZeneca ($AZN) announced a second deal in Asia in as many days to sell a noncore drug, fetching $70 million from a unit of Tokyo-based Kyowa Hakko Kirin. The latest deal sees ProStrakan, based in Galashiels, Scotland, buy European rights to Moventig, a drug that treats opioid-induced constipation, AstraZeneca said in a press release. ProStrakan will also pay AstraZeneca unspecified tiered double-digit royalties and potential milestones. On Monday, the company announced a deal with third-party distributor China Medical Systems Holding for rights to two cardio drugs that garnered $500 million. The effort by AstraZeneca to shed noncore drugs is aimed at building cash pile for pipeline products that hold blockbuster promise. Release

> India's Odisha state plans to build industrial parks for API manufacture. Report

> The process of setting fees charged by Japan's hospitals, pharmacies and medical personnel under the Central Social Insurance Medical Council, or Chuikyo, has come into the spotlight ahead of fee revisions slated to come into notice on April 1. Report

> U.S.-based Medidata announced that Beijing-based R&G Pharma Studies became the first Chinese customer to use Medidata's clinical trial management technology Medidata CTMS. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.